The latest announcement is out from Avita Medical ( (RCEL) ).
On March 17, 2025, AVITA Medical Americas, LLC, a subsidiary of AVITA Medical, Inc., entered into a contract manufacturing agreement with Stedical Scientific, Inc. to produce PermeaDerm® Biosynthetic Wound Matrix in the U.S. This agreement, effective immediately, aims to enhance AVITA Medical’s production capabilities and meet growing market demand while optimizing cost efficiencies. Additionally, an amendment to the exclusive distribution agreement between the two companies was made, increasing AVITA Medical’s revenue share from PermeaDerm sales to 60% and establishing performance-based milestones. These strategic agreements are expected to strengthen the collaboration between AVITA Medical and Stedical Scientific, ensuring a robust supply chain and expanding the reach of PermeaDerm in the global market.
More about Avita Medical
AVITA Medical, Inc. is a leading therapeutic acute wound care company known for delivering transformative solutions aimed at optimizing wound healing and accelerating patient recovery. The company’s flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects, utilizing a patient’s own skin to create Spray-On Skin Cells for improved clinical outcomes. AVITA Medical also holds exclusive rights to market and distribute PermeaDerm, a biosynthetic wound matrix, in the U.S.
YTD Price Performance: -33.15%
Average Trading Volume: 222,064
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $225.4M
For detailed information about RCEL stock, go to TipRanks’ Stock Analysis page.